Oncogenic IDH Mutations Increase Heterochromatin-related Replication Stress Without Impacting Homologous Recombination

Overview

Journal Mol Cell

Publisher Cell Press

Specialty Cell Biology

Date 2023 Jun 13

PMID 37311462

Authors

Juan-Manuel Schvartzman

Grace Forsyth

Henry Walch

Walid Chatila

Angelo Taglialatela

Brian J Lee

Xiaolu Zhu

Steven Gershik

Francesco V Cimino

Anthony Santella

Kamal Menghrajani

Alberto Ciccia

Richard Koche

Francisco Sanchez-Vega

Shan Zha

Craig B Thompson

Affiliations

Soon will be listed here.

Abstract

Oncogenic mutations in isocitrate dehydrogenases 1 and 2 (IDH1/2) produce 2-hydroxyglutarate (2HG), which inhibits dioxygenases that modulate chromatin dynamics. The effects of 2HG have been reported to sensitize IDH tumors to poly-(ADP-ribose) polymerase (PARP) inhibitors. However, unlike PARP-inhibitor-sensitive BRCA1/2 tumors, which exhibit impaired homologous recombination, IDH-mutant tumors have a silent mutational profile and lack signatures associated with impaired homologous recombination. Instead, 2HG-producing IDH mutations lead to a heterochromatin-dependent slowing of DNA replication accompanied by increased replication stress and DNA double-strand breaks. This replicative stress manifests as replication fork slowing, but the breaks are repaired without a significant increase in mutation burden. Faithful resolution of replicative stress in IDH-mutant cells is dependent on poly-(ADP-ribosylation). Treatment with PARP inhibitors increases DNA replication but results in incomplete DNA repair. These findings demonstrate a role for PARP in the replication of heterochromatin and further validate PARP as a therapeutic target in IDH-mutant tumors.

Citing Articles

Lipoylation inhibition enhances radiation control of lung cancer by suppressing homologous recombination DNA damage repair.

Chiang J, Shang Z, Rosales T, Cai L, Chen W, Cai F Sci Adv. 2025; 11(11):eadt1241.

PMID: 40073141 PMC: 11900879. DOI: 10.1126/sciadv.adt1241.

D-2-hydroxyglutarate impairs DNA repair through epigenetic reprogramming.

Lang F, Kaur K, Fu H, Zaheer J, Ribeiro D, Aladjem M Nat Commun. 2025; 16(1):1431.

PMID: 39920158 PMC: 11806014. DOI: 10.1038/s41467-025-56781-2.

PARP inhibition-associated heterochromatin confers increased DNA replication stress and vulnerability to ATR inhibition in SMARCA4-deficient cells.

Yano K, Kato M, Endo S, Igarashi T, Wada R, Kohno T Cell Death Discov. 2025; 11(1):31.

PMID: 39875375 PMC: 11775187. DOI: 10.1038/s41420-025-02306-1.

Metabolism-driven chromatin dynamics: Molecular principles and technological advances.

Sahu V, Lu C Mol Cell. 2025; 85(2):262-275.

PMID: 39824167 PMC: 11750176. DOI: 10.1016/j.molcel.2024.12.012.

Oncogenic IDH1 drives robust loss of histone acetylation and increases chromatin heterogeneity.

Furth N, Cohen N, Spitzer A, Salame T, Dassa B, Mehlman T Proc Natl Acad Sci U S A. 2025; 122(1):e2403862122.

PMID: 39793065 PMC: 11725805. DOI: 10.1073/pnas.2403862122.

References

Liu X, Jiang W, Dubois R, Yamamoto K, Wolner Z, Zha S . Overlapping functions between XLF repair protein and 53BP1 DNA damage response factor in end joining and lymphocyte development. Proc Natl Acad Sci U S A. 2012; 109(10):3903-8. PMC: 3309750. DOI: 10.1073/pnas.1120160109. View

Guetg C, Lienemann P, Sirri V, Grummt I, Hernandez-Verdun D, Hottiger M . The NoRC complex mediates the heterochromatin formation and stability of silent rRNA genes and centromeric repeats. EMBO J. 2010; 29(13):2135-46. PMC: 2905252. DOI: 10.1038/emboj.2010.17. View

Pope B, Ryba T, Dileep V, Yue F, Wu W, Denas O . Topologically associating domains are stable units of replication-timing regulation. Nature. 2014; 515(7527):402-5. PMC: 4251741. DOI: 10.1038/nature13986. View

Dang L, White D, Gross S, Bennett B, Bittinger M, Driggers E . Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462(7274):739-44. PMC: 2818760. DOI: 10.1038/nature08617. View

Nunez F, Mendez F, Kadiyala P, Alghamri M, Savelieff M, Garcia-Fabiani M . IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response. Sci Transl Med. 2019; 11(479). PMC: 6400220. DOI: 10.1126/scitranslmed.aaq1427. View

Menolfi D, Jiang W, Lee B, Moiseeva T, Shao Z, Estes V . Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA. Nat Commun. 2018; 9(1):5351. PMC: 6297235. DOI: 10.1038/s41467-018-07798-3. View

Techer H, Koundrioukoff S, Azar D, Wilhelm T, Carignon S, Brison O . Replication dynamics: biases and robustness of DNA fiber analysis. J Mol Biol. 2013; 425(23):4845-55. DOI: 10.1016/j.jmb.2013.03.040. View

Ayyanathan K, Lechner M, Bell P, Maul G, Schultz D, Yamada Y . Regulated recruitment of HP1 to a euchromatic gene induces mitotically heritable, epigenetic gene silencing: a mammalian cell culture model of gene variegation. Genes Dev. 2003; 17(15):1855-69. PMC: 196232. DOI: 10.1101/gad.1102803. View

Shen R, Seshan V . FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016; 44(16):e131. PMC: 5027494. DOI: 10.1093/nar/gkw520. View

10.

Garcia-Cao M, OSullivan R, Peters A, Jenuwein T, Blasco M . Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat Genet. 2004; 36(1):94-9. DOI: 10.1038/ng1278. View

11.

van Sluis M, McStay B . Nucleolar reorganization in response to rDNA damage. Curr Opin Cell Biol. 2017; 46:81-86. DOI: 10.1016/j.ceb.2017.03.004. View

12.

Popova T, Manie E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T . Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res. 2012; 72(21):5454-62. DOI: 10.1158/0008-5472.CAN-12-1470. View

13.

Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J . OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol. 2017; 2017. PMC: 5586540. DOI: 10.1200/PO.17.00011. View

14.

van Sluis M, McStay B . A localized nucleolar DNA damage response facilitates recruitment of the homology-directed repair machinery independent of cell cycle stage. Genes Dev. 2015; 29(11):1151-63. PMC: 4470283. DOI: 10.1101/gad.260703.115. View

15.

Sulkowski P, Oeck S, Dow J, Economos N, Mirfakhraie L, Liu Y . Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature. 2020; 582(7813):586-591. PMC: 7319896. DOI: 10.1038/s41586-020-2363-0. View

16.

Ward P, Patel J, Wise D, Abdel-Wahab O, Bennett B, Coller H . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225-34. PMC: 2849316. DOI: 10.1016/j.ccr.2010.01.020. View

17.

Farmer H, McCabe N, Lord C, Tutt A, Johnson D, Richardson T . Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005; 434(7035):917-21. DOI: 10.1038/nature03445. View

18.

Cong K, Peng M, Nedergaard Kousholt A, Lee W, Lee S, Nayak S . Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell. 2021; 81(15):3128-3144.e7. PMC: 9089372. DOI: 10.1016/j.molcel.2021.06.011. View

19.

Peng J, Karpen G . H3K9 methylation and RNA interference regulate nucleolar organization and repeated DNA stability. Nat Cell Biol. 2006; 9(1):25-35. PMC: 2819265. DOI: 10.1038/ncb1514. View

20.

Zehir A, Benayed R, Shah R, Syed A, Middha S, Kim H . Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017; 23(6):703-713. PMC: 5461196. DOI: 10.1038/nm.4333. View